Degarelix (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Degarelix" in English language version.

refsWebsite

Global rank English rank

10nih.gov

4^th place

9web.archive.org

1^st place

7doi.org

2^nd place

2drugs.com

399^th place

333^rd place

2semanticscholar.org

11^th place

8^th place

1medicines.org.uk

3,823^rd place

2,387^th place

1europa.eu

68^th place

117^th place

1felleskatalogen.no

low place

1fda.gov

447^th place

338^th place

1prnewswire.co.uk

6,376^th place

4,260^th place

1expressen.se

805^th place

1,216^th place

doi.org

Princivalle M, Broqua P, White R, Meyer J, Mayer G, Elliott L, et al. (March 2007). "Rapid suppression of plasma testosterone levels and tumor growth in the dunning rat model treated with degarelix, a new gonadotropin-releasing hormone antagonist". The Journal of Pharmacology and Experimental Therapeutics. 320 (3): 1113–8. doi:10.1124/jpet.106.112326. PMID 17179469. S2CID 2892725.
Clinton TN, Woldu SL, Raj GV (June 2017). "Degarelix versus luteinizing hormone-releasing hormone agonists for the treatment of prostate cancer". Expert Opinion on Pharmacotherapy. 18 (8): 825–832. doi:10.1080/14656566.2017.1328056. PMC 7171911. PMID 28480768.
Gittelman M, Pommerville PJ, Persson BE, Jensen JK, Olesen TK (November 2008). "A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America". The Journal of Urology. 180 (5): 1986–92. doi:10.1016/j.juro.2008.07.033. PMID 18801505.
Van Poppel H, Tombal B, de la Rosette JJ, Persson BE, Jensen JK, Kold Olesen T (October 2008). "Degarelix: a novel gonadotropin-releasing hormone (GnRH) receptor blocker--results from a 1-yr, multicentre, randomised, phase 2 dosage-finding study in the treatment of prostate cancer". European Urology. 54 (4): 805–13. doi:10.1016/j.eururo.2008.04.065. PMID 18538469.
Klotz L, Boccon-Gibod L, Shore ND, Andreou C, Persson BE, Cantor P, et al. (December 2008). "The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer". BJU Int. 102 (11): 1531–8. doi:10.1111/j.1464-410X.2008.08183.x. PMID 19035858. S2CID 8280692.
van Poppel H, Nilsson S (June 2008). "Testosterone surge: rationale for gonadotropin-releasing hormone blockers?". Urology. 71 (6): 1001–6. doi:10.1016/j.urology.2007.12.070. PMID 18407326.
Landgren V, Malki K, Bottai M, Arver S, Rahm C (April 2020). "Effect of Gonadotropin-Releasing Hormone Antagonist on Risk of Committing Child Sexual Abuse in Men With Pedophilic Disorder: A Randomized Clinical Trial". JAMA Psychiatry. 77 (9): 897–905. doi:10.1001/jamapsychiatry.2020.0440. PMC 7191435. PMID 32347899.

drugs.com

"Degarelix (Firmagon) Use During Pregnancy". Drugs.com. 3 February 2020. Archived from the original on 26 February 2020. Retrieved 25 February 2020.
"Degarelix Acetate Monograph for Professionals". Drugs.com. 7 October 2019. Archived from the original on 26 February 2020. Retrieved 25 February 2020.

europa.eu

ema.europa.eu

"Firmagon EPAR". European Medicines Agency (EMA). 10 January 2020. Archived from the original on 26 February 2020. Retrieved 25 February 2020.

expressen.se

"Pedofiler ska stoppas – med kemisk kastrering". Expressen. Archived from the original on 26 February 2021. Retrieved 4 August 2016.

fda.gov

accessdata.fda.gov

"Drug Approval Package: Degarelix NDA #022201". U.S. Food and Drug Administration (FDA). Archived from the original on 9 August 2020. Retrieved 29 September 2020.

felleskatalogen.no

"Firmagon "Ferring Pharmaceuticals A/S" - Felleskatalogen". www.felleskatalogen.no. Archived from the original on 28 November 2020. Retrieved 5 May 2020.

medicines.org.uk

"Firmagon 120mg Injection - Summary of Product Characteristics (SmPC)". (emc). 15 January 2020. Archived from the original on 26 February 2020. Retrieved 25 February 2020.

nih.gov

pubmed.ncbi.nlm.nih.gov

Princivalle M, Broqua P, White R, Meyer J, Mayer G, Elliott L, et al. (March 2007). "Rapid suppression of plasma testosterone levels and tumor growth in the dunning rat model treated with degarelix, a new gonadotropin-releasing hormone antagonist". The Journal of Pharmacology and Experimental Therapeutics. 320 (3): 1113–8. doi:10.1124/jpet.106.112326. PMID 17179469. S2CID 2892725.
Clinton TN, Woldu SL, Raj GV (June 2017). "Degarelix versus luteinizing hormone-releasing hormone agonists for the treatment of prostate cancer". Expert Opinion on Pharmacotherapy. 18 (8): 825–832. doi:10.1080/14656566.2017.1328056. PMC 7171911. PMID 28480768.
Gittelman M, Pommerville PJ, Persson BE, Jensen JK, Olesen TK (November 2008). "A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America". The Journal of Urology. 180 (5): 1986–92. doi:10.1016/j.juro.2008.07.033. PMID 18801505.
Van Poppel H, Tombal B, de la Rosette JJ, Persson BE, Jensen JK, Kold Olesen T (October 2008). "Degarelix: a novel gonadotropin-releasing hormone (GnRH) receptor blocker--results from a 1-yr, multicentre, randomised, phase 2 dosage-finding study in the treatment of prostate cancer". European Urology. 54 (4): 805–13. doi:10.1016/j.eururo.2008.04.065. PMID 18538469.
Klotz L, Boccon-Gibod L, Shore ND, Andreou C, Persson BE, Cantor P, et al. (December 2008). "The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer". BJU Int. 102 (11): 1531–8. doi:10.1111/j.1464-410X.2008.08183.x. PMID 19035858. S2CID 8280692.
van Poppel H, Nilsson S (June 2008). "Testosterone surge: rationale for gonadotropin-releasing hormone blockers?". Urology. 71 (6): 1001–6. doi:10.1016/j.urology.2007.12.070. PMID 18407326.
Landgren V, Malki K, Bottai M, Arver S, Rahm C (April 2020). "Effect of Gonadotropin-Releasing Hormone Antagonist on Risk of Committing Child Sexual Abuse in Men With Pedophilic Disorder: A Randomized Clinical Trial". JAMA Psychiatry. 77 (9): 897–905. doi:10.1001/jamapsychiatry.2020.0440. PMC 7191435. PMID 32347899.

ncbi.nlm.nih.gov

Clinton TN, Woldu SL, Raj GV (June 2017). "Degarelix versus luteinizing hormone-releasing hormone agonists for the treatment of prostate cancer". Expert Opinion on Pharmacotherapy. 18 (8): 825–832. doi:10.1080/14656566.2017.1328056. PMC 7171911. PMID 28480768.
Landgren V, Malki K, Bottai M, Arver S, Rahm C (April 2020). "Effect of Gonadotropin-Releasing Hormone Antagonist on Risk of Committing Child Sexual Abuse in Men With Pedophilic Disorder: A Randomized Clinical Trial". JAMA Psychiatry. 77 (9): 897–905. doi:10.1001/jamapsychiatry.2020.0440. PMC 7191435. PMID 32347899.

dailymed.nlm.nih.gov

"Firmagon- degarelix kit". DailyMed. 18 September 2019. Archived from the original on 12 August 2020. Retrieved 26 February 2020.

prnewswire.co.uk

"FDA Approves Ferring Pharmaceuticals' Degarelix (Generic Name) for Treatment of Advanced Prostate Cancer" (Press release). Ferring Pharmaceuticals. 24 December 2008. Archived from the original on 8 June 2011. Retrieved 25 February 2020 – via PR Newswire.

semanticscholar.org

api.semanticscholar.org

Princivalle M, Broqua P, White R, Meyer J, Mayer G, Elliott L, et al. (March 2007). "Rapid suppression of plasma testosterone levels and tumor growth in the dunning rat model treated with degarelix, a new gonadotropin-releasing hormone antagonist". The Journal of Pharmacology and Experimental Therapeutics. 320 (3): 1113–8. doi:10.1124/jpet.106.112326. PMID 17179469. S2CID 2892725.
Klotz L, Boccon-Gibod L, Shore ND, Andreou C, Persson BE, Cantor P, et al. (December 2008). "The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer". BJU Int. 102 (11): 1531–8. doi:10.1111/j.1464-410X.2008.08183.x. PMID 19035858. S2CID 8280692.

web.archive.org

"Degarelix (Firmagon) Use During Pregnancy". Drugs.com. 3 February 2020. Archived from the original on 26 February 2020. Retrieved 25 February 2020.
"Firmagon 120mg Injection - Summary of Product Characteristics (SmPC)". (emc). 15 January 2020. Archived from the original on 26 February 2020. Retrieved 25 February 2020.
"Firmagon- degarelix kit". DailyMed. 18 September 2019. Archived from the original on 12 August 2020. Retrieved 26 February 2020.
"Firmagon EPAR". European Medicines Agency (EMA). 10 January 2020. Archived from the original on 26 February 2020. Retrieved 25 February 2020.
"Degarelix Acetate Monograph for Professionals". Drugs.com. 7 October 2019. Archived from the original on 26 February 2020. Retrieved 25 February 2020.
"Firmagon "Ferring Pharmaceuticals A/S" - Felleskatalogen". www.felleskatalogen.no. Archived from the original on 28 November 2020. Retrieved 5 May 2020.
"Drug Approval Package: Degarelix NDA #022201". U.S. Food and Drug Administration (FDA). Archived from the original on 9 August 2020. Retrieved 29 September 2020.
"FDA Approves Ferring Pharmaceuticals' Degarelix (Generic Name) for Treatment of Advanced Prostate Cancer" (Press release). Ferring Pharmaceuticals. 24 December 2008. Archived from the original on 8 June 2011. Retrieved 25 February 2020 – via PR Newswire.
"Pedofiler ska stoppas – med kemisk kastrering". Expressen. Archived from the original on 26 February 2021. Retrieved 4 August 2016.